MSB 4.69% $1.45 mesoblast limited

COVID-19 ARDS and ARDS Share Price Scenarios, page-413

  1. 37 Posts.
    lightbulb Created with Sketch. 1
    Yep, totally take your point - although specifically for COVID19 I'm optimistic of a vaccine which will largely reduce the need for remestemcel-l to treat COVID19 patients with ARDS.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.